PD-1, however, may take several months to develop inflammatory and autoimmune diseases (88) and the resolution of irAEs induced by PD-1 treatment also take longer than CTLA-4 blockade (89).Thus, it is critical to further investigate the cellular/molecular mechanisms that cause these toxicities in order to develop safe and efficient therapeutic strategies. Here, CTLA4 is linked to autoimmune disease.